Phase III study ARANOTE to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) assessing the novel androgen-receptor antagonist in combination with standard androgen deprivation ...

ORION CORPORATION PRESS RELEASE 27 February 2023 at 9:00 EET Darolutamide receives approval for additional prostate cancer indication in Japan Darolutamide approved for metastatic prostate cancer as ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Darolutamide ...

New data suggest that adding darolutamide (Nubeqa) onto androgen deprivation therapy (ADT) and docetaxel should become a new standard of care for men with metastatic hormone-sensitive prostate cancer ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Swiss Group for ...

Darolutamide now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ...

Adding darolutamide to ADT and docetaxel improves overall survival in patients with metastatic hormone-sensitive prostate cancer. Adding darolutamide to androgen deprivation therapy (ADT) and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio The addition of darolutamide to docetaxel ...

Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.

Please provide your email address to receive an email when new articles are posted on . The regimen reduced risk for death by 32.5%. Data derived from Smith MR, et al. Abstract 13. Presented at: ASCO ...

LOS ANGELES, Oct. 25, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Bayer today announced two 2023 Bayer-PCF Darolutamide Challenge Awards totaling $2 million to support clinical ...

Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a ...